AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study will test the effectiveness of warfarin in patients with IPF. Approximately 256
patients will be randomized 1:1 to either warfarin or placebo. Patients will return at week 1
for a safety review and every 16 weeks for 48 weeks. The primary endpoint in the study is the
time to either death, non-bleeding/non-elective hospitalization, or a drop of greater than
10% in forced vital capacity (FVC) from baseline.
Phase:
Phase 3
Details
Lead Sponsor:
Duke University
Collaborators:
Duke Clinical Research Institute National Heart, Lung, and Blood Institute (NHLBI)